You are here: Industry Insights > Keytruda

News List

Another Anti-PD-L(1) Monoclonal Antibody Filed the IND Application in China to Join the 40+ Applicants! Sales of Keytruda to Rank Second in the World in 2019 PharmaSources/1°C
November 14, 2019
MSD released the Q3 financial report on Oct. 29, 2019. Its figures, especially the figures of its oncology business, were no longer shining, with keywords including Keytruda, Gardasil 9, and China.
Merck reimagines Keytruda patient support program as it celebrates 5th birthday fiercepharma
September 26, 2019
The Key+You program falls into the typical customer relationship management program, with about 5% of patients involved.
FDA Approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma drugs
September 23, 2019
Merck, known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration (FDA) approved the combination of Keytruda ...
FDA Approves Keytruda (pembrolizumab) for the Treatment of Metastatic Small Cell Lung Cancer (SCLC) drugs
June 19, 2019
FDA Approves Keytruda (pembrolizumab) for the Treatment of Metastatic Small Cell Lung Cancer (SCLC).
FDA Approves Keytruda (pembrolizumab) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma drugs
June 12, 2019
FDA Approves Keytruda (pembrolizumab) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma.
Charity LifeArc sells rights to Keytruda for more than $1bn pharmaceutical-technology
May 22, 2019
UK-based medical research charity LifeArc has sold its royalty interest in Merck’s Keytruda (pembrolizumab) for $1.297bn to the European subsidiary of Canada Pension Plan Investment Board (CPPIB).
MSD’s Keytruda falls short in late stage breast cancer study pharmatimes
May 21, 2019
MSD has announced that its anti-PD-1 therapy Keytruda has failed to meet its primary endpoint in a late-stage study testing the drug as a standalone treatment in patients with metastatic triple-negative breast cancer (TNBC).
KEYTRUDA Meets Primary Trial Endpoint as Monotherapy and in Combination with Chemotherapy americanpharmaceuticalreview
April 28, 2019
KEYTRUDA Meets Primary Trial Endpoint as Monotherapy and in Combination with Chemotherapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Eli Lilly, Avidity Biosciences announce $35M immunology research deal pharmatimes
April 24, 2019
The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab), in combination with Inlyta(axitinib), as first-line treatment for patients with advanced renal cell carcinoma (RCC).
Merck’s Keytruda gets FDA approval to treat kidney cancer pharmaceutical-technology
April 24, 2019
Merck has received US Food and Drug Administration (FDA) approval for its anti-PD-1 therapy Keytruda to treat advanced renal cell carcinoma (RCC) patients.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page